跳轉至內容
Merck
  • Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.

Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.

Journal of neuroimmunology (2013-03-23)
Shaher Duchi, Haim Ovadia, Elka Touitou
摘要

We investigated the efficiency of nasal drug administration as a new non-invasive treatment strategy for MS. Glatiramer Acetate (GA) and GA-Cannabidiol (CBD) combination administered in nasal delivery system (NDS) resulted in a statistically significant decrease of clinical scores and inflammatory cytokine expression in experimental autoimmune encephalomyelitis (EAE) mice. Even a suboptimal dose of Prednisolone in NDS was effective in preventing the clinical signs of the disease. Neuron regeneration was observed in the hippocampus of EAE mice treated with GA-CBD in NDS. This work shows that nasal administration improved drug efficiency and stimulates further research for a non-invasive strategy for MS.

材料
產品編號
品牌
產品描述

Supelco
大麻二酚标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
大麻二酚标准液 溶液, 1.0 mg/mL in methanol, analytical standard, for drug analysis
Supelco
大麻二酚标准液 溶液, ~10 mg/mL in ethanol, analytical standard, for drug analysis